Interventional pharmacoeconomics: A new discipline for a cost-constrained environment

2:25 pm-3:05 pm

Room: Lomond Auditorium

Programme stream(s): Treatment
Programme session type(s): Plenary session

Chair: Ruth Plummer, Northern Centre for Cancer Treatment
Speaker: Mark Ratain, University of Chicago

Interventional pharmacoeconomics is an emerging discipline at the intersection of clinical trials and pharmacoeconomics, aiming to reduce prescribing costs through the development of off-label treatment regimens. There are four basic strategies to reduce costs and potentially toxicity, without negatively impacting efficacy: 1) substitution of a therapeutic alternative (e.g., sirolimus for everolimus); 2) lower dosages (e.g., abiraterone 250 mg with food); 3) less frequent dosing (e.g., nivolumab 480 mg every 8 weeks); 4) shorter duration of dosing (e.g., PERSEPHONE study). Notably, in a single payer system such as the NHS, these studies are self-funding, if the drug savings accrued during the study (in the experimental arm) can be repurposed to fund the research costs.